CClinicalTrials.gg
CompletedNCT00005730Updated Jun 24, 2005

National Marrow Donor Program (NMDP)

An observational study in Bone Marrow Transplantation, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Completed. Open to male participants. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational

Study type
Observational
Sex
Male
01

Study summary

To serve as a focal point for bone-marrow research.

Read the detailed description

BACKGROUND:

In 1986, the Department of the Navy initiated the National Bone Marrow Donor Registry. Because the support of a National Bone Marrow Donor Registry was not very closely related to the Navy's primary missions, in 1989 the management of the contract for the program was transferred by the Congress from the Navy to the NHLBI.

By 1989, bone marrow transplantation had become an effective and accepted treatment for an increasing number of diseases of the bone marrow and the immune system. Until only a few years prior to 1989, most marrow donors were siblings, carefully matched for HLA (tissue) antigens. Since only a small proportion of candidates for a bone marrow transplant have matched brothers or sisters, additional family members were tried as donors. These included parents, children, slightly mismatched siblings, and other relatives. Even with the broadening of the bone marrow donor source, no more than 30-40 percent of patients with diseases amenable to marrow transplant therapy had available donors. Improved results with these selectively mismatched relatives and a distinct need to provide appropriate treatment for more patients led to trials with unrelated, HLA-matched community volunteers as bone marrow donors. By 1989, research had progressed to the point where transplants from such unrelated donors were nearly as successful as those from matched siblings, when stratified by disease status and risk parameters. In 1989, 20 to 25 percent of patients for whom a formal donor search was initiated received a transplant. This was expected to increase substantially.

DESIGN NARRATIVE:

The program was established by the Department of the Navy in 1986 and transferred to the NHLBI in 1989. The purpose was to develop and maintain a registry of individuals willing to donate bone marrow for patients in need of transplants, to facilitate marrow transplants by serving as a coordinating and communications center for a network of donor, collection and transplant centers in the United States and internationally, and to facilitate research into the efficacy of unrelated donor marrow transplants. In 1992, the program was enlarged to support a limited number of demonstration projects to develop, implement, and evaluate innovative models for minority marrow donor recruitment. In 1995, the NMDP was transferred to the Health Resources and Services Administration (HRSA), although NHLBI provided funds in this year.

02

Conditions studied

  • Bone Marrow Transplantation
03

In context

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,117 studies on the registry; 71 are open to participants now.

Of its 57 completed or terminated interventional studies of FDA-regulated products, 49 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

No eligibility criteria

05

Study design

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Zumwalt ER Jr, Howe CW. The origins and development of the National Marrow Donor Program. Leukemia. 1993 Jul;7(7):1122. No abstract available. PubMed 8321042 ↗
  • Ng J, Hurley CK, Carter C, Baxter-Lowe LA, Bing D, Chopek M, Hegland J, Lee TD, Li TC, Hsu S, KuKuruga D, Mason JM, Monos D, Noreen H, Rosner G, Schmeckpeper B, Dupont B, Hartzman RJ. Large-scale DRB and DQB1 oligonucleotide typing for the NMDP registry: progress report from year 2. Tissue Antigens. 1996 Jan;47(1):21-6. doi: 10.1111/j.1399-0039.1996.tb02510.x. PubMed 8929709 ↗
  • Freytes CO, Beatty PG. Representation of Hispanics in the National Marrow Donor Program. Bone Marrow Transplant. 1996 Mar;17(3):323-7. PubMed 8704681 ↗
  • Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation. 1995 Oct 27;60(8):778-83. PubMed 7482734 ↗
  • Perkins HA, Kollman C, Howe CW. Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program. Clin Transpl. 1994:295-301. PubMed 7547550 ↗
  • Perkins HA, Hansen JA. The U.S. National Marrow Donor Program. Am J Pediatr Hematol Oncol. 1994 Feb;16(1):30-4. PubMed 8311171 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00005730
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
First posted
May 26, 2000
Start date
Jan 1989
Completion
Dec 1995
Last update
Jun 24, 2005

Study contacts

Patrick Beatty
Bloodworks
Craig Howe
National Marrow Donor Program, Inc.
Jay Menitove
Blood Center of Southeastern Wisconsin
David Stronek
American National Red Cross
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion